mPhase New Patent Application Would Protect the Delivery of Preset Topical Dosages
NanoDermatology Society Declares 2013 the Year of Topical Delivery
(firmenpresse) - LITTLE FALLS, NJ -- (Marketwire) -- 02/27/13 -- mPhase Technologies, Inc. (OTCBB: XDSL) announced today that on the heels of filing a US letter patent application for automatic dispensing of preset dosages for a drug delivery system that the Nanodermatology Society declared 2013 the year of Topical Delivery.
mPhase believes that, if issued, its new application would protect the delivery of pre set dosages of a drug agent or medication topically.
Delivery of medication to and through the skin has long been known to offer advantages over oral or intravenous routes. Such application avoids the damaging effects of liver metabolism that can also reduce the effectiveness of a medication. By allowing control over the dosing through automatic dispensing of precise amounts of medications the benefits of healing can be achieved. This also reduces damage to other organs.
With this new patent application mPhase has broadened its Smart Surface Technology into the rapidly expanding field of medical devices.
About mPhase Technologies, Inc.
mPhase Technologies is introducing a revolutionary Smart Surface technology enabled by breakthroughs in nanotechnology, MEMS processing and microfluidics. Our Smart Surface technology has potential applications within drug delivery systems, lab-on-a-chip analytic systems, self-cleaning systems, liquid and chemical sensor systems, and filtration systems. mPhase has pioneered its first Smart Surface enabled product, the mPhase Smart NanoBattery. In addition to the Smart Surface technology, mPhase recently introduced its first product, the mPower Emergency Illuminator, an award-winning product designed by Porsche Design Studio and sold via the mPower website: . More information about the company can be found at .
Forward-Looking Statements
As a cautionary note to investors, certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; and all the risks and related information described from time to time in the Company's SEC filings, including the financial statements and related information contained in the Company's SEC Filing. mPhase assumes no obligation to update the information in this release.
Contact:
mPhase Technologies, Inc.
973-256-3737
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 27.02.2013 - 08:10 Uhr
Sprache: Deutsch
News-ID 1201422
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
LITTLE FALLS, NJ
Phone:
Kategorie:
Electronics & Communications
Anmerkungen:
Diese Pressemitteilung wurde bisher 171 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"mPhase New Patent Application Would Protect the Delivery of Preset Topical Dosages
"
steht unter der journalistisch-redaktionellen Verantwortung von
mPhase Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
